White House Omissions: Cannabis Rescheduling Left Out of Latest Drug Policy Plan
The White House Office of National Drug Control Policy has released a new report outlining the Trump administration’s top drug policy priorities, but surprisingly, it fails to mention any plans to reschedule marijuana or implement other cannabis reforms.
The report focuses on combating the opioid epidemic, addressing methamphetamine and other drug-related issues, and promoting international cooperation to disrupt drug trafficking. However, it neglects to address the growing debate around cannabis legalization and regulation.
Meanwhile, other developments in the cannabis industry include:
* The Department of Veterans Affairs is seeking contractors to analyze and explain scientific evidence on medical marijuana, including its potential benefits for conditions like PTSD and potential risks related to cannabis use disorder.
* The House Oversight and Government Reform Committee will hold a hearing on the Food and Drug Administration’s handling of hemp products, featuring testimony from the U.S. Hemp Roundtable.
* Reps. Lou Correa (D-CA) and Jack Bergman (R-MI) have introduced a bill to provide $30 million for psychedelics-focused “centers for excellence” within the Department of Veterans Affairs.
* The Florida House Health Professions and Programs Subcommittee has approved a bill to waive medical cannabis patient registration fees for military veterans and reduce the frequency of card renewals.
These developments come as Americans increasingly view marijuana as safer than alcohol and cigarettes, according to a recent survey.
